Bell Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$74.5K Buy
150
+21
+16% +$9.31K 0.01% 213
2026
Q1
$57.6K Sell
129
-3
-2% -$1.4K 0.01% 231
2025
Q4
$59.8K Buy
132
+27
+26% +$11.6K 0.01% 234
2025
Q3
$41.1K Sell
105
-10
-9% -$4.18K 0.01% 268
2025
Q2
$51.2K Hold
115
– – 0.01% 243
2025
Q1
$55.8K Sell
115
-2
-2% -$932 0.01% 211
2024
Q4
$47.1K Sell
117
-3
-3% -$1.39K 0.01% 227
2024
Q3
$55.8K Hold
120
– – 0.01% 215
2024
Q2
$56.2K Buy
120
+1
+0.8% +$434 0.01% 201
2024
Q1
$49.7K Buy
119
+9
+8% +$3.81K 0.01% 207
2023
Q4
$44.8K Buy
110
+3
+3% +$1.11K 0.01% 210
2023
Q3
$37.2K Buy
107
+4
+4% +$1.4K 0.01% 209
2023
Q2
$36.2K Buy
103
+10
+11% +$3.37K 0.01% 206
2023
Q1
$29.3K Sell
93
-10
-10% -$3K 0.01% 235
2022
Q4
$29.7K Buy
103
+11
+12% +$3.35K 0.01% 235
2022
Q3
$27K Sell
92
-4
-4% -$1.15K 0.01% 217
2022
Q2
$27K Buy
+96
New +$25.7K 0.01% 219
2021
Q4
$18K Buy
80
+70
+700% +$13.6K ﹤0.01% 344
2021
Q3
$2K Buy
+10
New +$1.95K ﹤0.01% 1180

Other funds holding VRTX

Bell Investment Advisors's VRTX Position: Q2 2026 in Review

Bell Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q2 2026, buying an estimated $9.31K and bringing the position to 150 shares worth $74.5K. The position accounts for 0.01% of the portfolio, ranked #213.

Bell Investment Advisors first reported a position in VRTX in Q3 2021 and has held it in 19 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bell Investment Advisors held 150 shares of Vertex Pharmaceuticals worth $74.5K as of Q2 2026.
  • Bell Investment Advisors bought 21 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.31K.
  • Vertex Pharmaceuticals made up 0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #213 holding.
  • Bell Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.